Current Report Filing (8-k)
September 05 2019 - 6:01AM
Edgar (US Regulatory)
DANAHER CORP /DE/ DC false 0000313616 0000313616 2019-09-03 2019-09-03 0000313616 us-gaap:CommonStockMember 2019-09-03 2019-09-03 0000313616 us-gaap:ConvertiblePreferredStockMember 2019-09-03 2019-09-03 0000313616 dhr:FloatingRateSeniorNotesDue2022Member 2019-09-03 2019-09-03 0000313616 dhr:M1.700PercentSeniorNotesDue2022Member 2019-09-03 2019-09-03 0000313616 dhr:M2.500PercentSeniorNotesDue2025Member 2019-09-03 2019-09-03 0000313616 dhr:M1.200PercentSeniorNotesDue2027Member 2019-09-03 2019-09-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 3, 2019
Danaher Corporation
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-08089
|
|
59-1995548
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2200 Pennsylvania Ave., N.W., Suite 800W
Washington, D.C.
|
|
20037-1701
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: 202-828-0850
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.01 par value
|
|
DHR
|
|
New York Stock Exchange
|
4.75% Mandatory Convertible Preferred Stock, Series A, without par value
|
|
DHR.PRA
|
|
New York Stock Exchange
|
Floating Rate Senior Notes due 2022
|
|
DHR F 06/30/22
|
|
New York Stock Exchange
|
1.700% Senior Notes due 2022
|
|
DHR 1.7 01/04/22
|
|
New York Stock Exchange
|
2.500% Senior Notes due 2025
|
|
DHR 2.5 07/08/25
|
|
New York Stock Exchange
|
1.200% Senior Notes due 2027
|
|
DHR 1.2 06/30/27
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On September 3, 2019, DH Europe Finance II S.à r.l. (“Danaher International II”) and Danaher Corporation (“Danaher”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Bank PLC, BNP Paribas, Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Banco Santander, S.A., and the several other underwriters party thereto for the issue and sale by Danaher International II of €1.25 billion aggregate principal amount of 0.200% Senior Notes due 2026 (the “2026 Notes”), €1.25 billion aggregate principal amount of 0.450% Senior Notes due 2028 (the “2028 Notes”), €1.75 billion aggregate principal amount of 0.750% Senior Notes due 2031 (the “2031 Notes”), €1.25 billion aggregate principal amount of 1.350% Senior Notes due 2039 (the “2039 Notes”) and €750 million aggregate principal amount of 1.800% Senior Notes due 2049 (the “2049 Notes,” and collectively with the 2026 Notes, the 2028 Notes, the 2031 Notes and the 2039 Notes, the “Notes”), in an underwritten offering. The Notes will be fully and unconditionally guaranteed by Danaher. The Underwriting Agreement contains customary representations, warranties and agreements of Danaher and Danaher International II, customary conditions to closing, termination provisions and indemnification and other obligations of the parties.
Danaher International II expects to receive net proceeds, after underwriting discounts and estimated offering expenses, of approximately €6.197 billion. Danaher anticipates using the net proceeds to fund a portion of the cash consideration payable for, and certain costs associated with, its acquisition of the Biopharma Business of GE Life Sciences (the “GE Biopharma Acquisition”). Pending completion of the GE Biopharma Acquisition, Danaher may invest the net proceeds of the offering in short-term bank deposits or invest them in interest-bearing, investment-grade securities. The offering of the Notes is expected to close on September 18, 2019, subject to customary closing conditions.
The above description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement. The Underwriting Agreement is filed as Exhibit 1.1 hereto, and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
The following exhibits are filed herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DANAHER CORPORATION
|
|
|
|
|
|
|
|
Date: September 4, 2019
|
|
|
|
By:
|
|
/s/ Matthew R. McGrew
|
|
|
|
|
Name:
|
|
Matthew R. McGrew
|
|
|
|
|
Title:
|
|
Executive Vice President and Chief
Financial Officer
|
Danaher (NYSE:DHR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Danaher (NYSE:DHR)
Historical Stock Chart
From Apr 2023 to Apr 2024